Company intelligence / Profile preview

Atacama Therapeutics, Inc.

Wellesley, Massachusetts, United Statesatacamatherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Atacama Therapeutics is a Massachusetts-based biotech company developing small molecule therapies for dermatological conditions. Its lead candidate, AT-5214 (dexmecamylamine), is in Phase II trials for both palmar hyperhidrosis and acne vulgaris. Previous studies have shown significant reduction in facial sebum production with AT-5214. The company has completed one Phase II trial and has another ongoing or recently completed as of early 2025.

Therapeutic areas: Dermatology
Modalities: Small molecules (notably dexmecamylamine/AT-5214)
Industry: Biotech

Partnerships

No major partnerships disclosed; previously related to University of South Florida Research Foundation as originator of the compound licensed by Atacama Therapeutics and others including AstraZeneca/Targacept in earlier development stages for other indications.

Beyond the preview

Go deeper on Atacama Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atacama Therapeutics, Inc..